Pillstats
Rx only · Tablet · Oral

Lasmiditan

Brands: Reyvow · Lasmiditan

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US2 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCN02CC08
RxCUI (US)2256930
US makers1 labelers
Packages6
DEA / ScheduleCV

US acquisition costNADAC · per unit

Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$25.52$51.04$76.56$102.08Dec 2025May 2026May 2026
$88.734
Latest avg · May 20, 2026
-0%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

9802.0K2.9K3.9K2025 Q12025 Q22025 Q32025 Q42026 Q1
2.0K
Rx · 2026 Q1
15K
Units dispensed
-36%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Eli Lilly and Companyunknown6SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Nov 3, 2025
    RESOLVEDShortage resolved: Lasmiditan Succinate Tablet (Eli Lilly and Co.)

    Lasmiditan Succinate Tablet — reported in shortage by Eli Lilly and Co.. Therapeutic category: Neurology.

  • Nov 3, 2025
    SHORTAGEDrug shortage: Lasmiditan Succinate Tablet (Eli Lilly and Co.)

    Lasmiditan Succinate Tablet — reported in shortage by Eli Lilly and Co.. Therapeutic category: Neurology.